ZoBio lands discovery contract with UCB

ZoBio of Leiden said pharmaceutical company UCB has selected it to provide ligand discovery services for fragment-based drug discovery. Under the agreement ZoBio will immobilise UCB targets and carry out ligand screening using its proprietary Target sNMR Screening (TINS) technology.

Using its TINS technology, ZoBio can rapidly generate high affinity, high specificity lead compounds with optimal drug-like properties. The company was founded in 2004 as a spinout from Leiden University